87 related articles for article (PubMed ID: 8303978)
1. [Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed].
Krawczyk W; Dmoszyńska A; Ledwozyw A; Soroka-Wojtaszko M
Acta Haematol Pol; 1993; 24(4):327-31. PubMed ID: 8303978
[TBL] [Abstract][Full Text] [Related]
2. Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients.
Krawczyk W; Dmoszyńska A; Marczewski K; Ledwozyw A
Exp Nephrol; 1995; 3(4):265-6. PubMed ID: 8590040
[TBL] [Abstract][Full Text] [Related]
3. [The influence of recombinant human erythropoietin on platelet phospholipid fatty acid composition in patients on long term hemodialysis].
Krawczyk W; Dmoszyńska A; Ledwozyw A
Pol Merkur Lekarski; 1996 Dec; 1(6):394-7. PubMed ID: 9273229
[TBL] [Abstract][Full Text] [Related]
4. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients.
Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB
Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286
[TBL] [Abstract][Full Text] [Related]
5. [The effect of human recombinant erythropoietin on levels of plasma phospholipids in patients chronically treated with hemodialysis].
Krawczyk W; Dmoszyńska A; Ledwozyw A; Marczewski K
Pol Arch Med Wewn; 1995 Jul; 94(1):21-5. PubMed ID: 8524695
[TBL] [Abstract][Full Text] [Related]
6. Expression of fibrinogen receptors and GPIIb molecules on uraemic platelets: effect of recombinant human erythropoietin therapy.
Krzesłowska J; Rysz J; Cierniewski CS; Luciak M
Nephrol Dial Transplant; 1995; 10(5):653-6. PubMed ID: 7566578
[TBL] [Abstract][Full Text] [Related]
7. [The effect of human recombinant erythropoietin on distribution of membrane phospholipids in blood platelets of patients with uremia treated with repeated hemodialysis].
Krawczyk W; Ledwozyw A; Dmoszyńska A; Krzywicka A; Rózyc P
Pol Arch Med Wewn; 1997 Feb; 97(2):120-5. PubMed ID: 9312760
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients.
Diaz-Ricart M; Etebanell E; Cases A; López-Pedret J; Castillo R; Ordinas A; Escolar G
Thromb Haemost; 1999 Oct; 82(4):1312-7. PubMed ID: 10544920
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
10. Influence of long-term erythropoietin treatment on insulin, glucagon, pancreatic polypeptide, and gastrin secretion in haemodialysed patients.
Kokot F; Nieszporek T; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Nephrol Dial Transplant; 1994; 9 Suppl 3():35-9. PubMed ID: 8072722
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link?
Van Geet C; Van Damme-Lombaerts R; Vanrusselt M; de Mol A; Proesmans W; Vermylen J
Thromb Haemost; 1990 Aug; 64(1):7-10. PubMed ID: 2274929
[TBL] [Abstract][Full Text] [Related]
12. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
[TBL] [Abstract][Full Text] [Related]
13. Selective modifications of the phospholipid fatty acid composition in human platelet membranes using nonspecific and specific lipid transfer proteins.
Bayon Y; Croset M; Guerbette F; Daveloose D; Chirouze V; Viret J; Kader JC; Lagarde M
Anal Biochem; 1995 Sep; 230(1):75-84. PubMed ID: 8585633
[TBL] [Abstract][Full Text] [Related]
14. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients.
Kokot F; Wiecek A; Mesjasz J; Adamczak M; Spiechowicz U
Nephrol Dial Transplant; 1998 May; 13(5):1200-5. PubMed ID: 9623554
[TBL] [Abstract][Full Text] [Related]
15. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.
Tang YD; Rinder HM; Katz SD
Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
